サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1586396

アミロイドーシス治療市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測、2024年～2032年

Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2024-2032

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
アミロイドーシス治療市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測、2024年～2032年
出版日: 2024年10月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、アミロイドーシス治療の世界市場規模は2032年までに97億9,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

アミロイドーシス治療市場は、広範なヘルスケア展望の重要なセグメントです。アミロイドーシス治療市場は、様々な組織や臓器にアミロイドタンパク質が異常沈着することを特徴とする、稀ではあるが重篤な疾患群に対する治療法に焦点を当てています。アミロイドーシスは、AL型（軽鎖）、AA型（二次性）、遺伝性型、野生型ATTR（トランスサイレチンアミロイドーシス）など、いくつかのタイプに分類されます。これらの病態は複雑であるため、多様な治療選択肢が必要であり、これが市場の著しい進歩につながっています。

アミロイドーシス治療市場は、疾患メカニズムの深い理解と診断技術の向上により、数十年にわたり継続的に発展してきました。歴史的には、アミロイドーシスの治療選択肢は限られており、しばしば患者の予後を悪くしていました。しかし、ダラツムマブやタファミジスのような新規治療薬のイントロダクションより、アミロイドーシスの治療法は大きく変わりました。

世界のアミロイドーシス治療市場は、認知度の向上、進行中の研究開発、高齢化人口の増加など、いくつかの要因により拡大しています。さらに、画像診断やバイオマーカー同定などの診断技術の進歩により、アミロイドーシスの効果的な治療に不可欠な早期診断が容易になっています。

アミロイドーシス治療市場レポートハイライト

アミロイドーシス治療市場において、エンドユーズに基づくと、患者中心の治療に対する嗜好の高まりにより、在宅ケア部門は予測期間中に大幅な成長が見込まれます。

病院・診療所セグメントは、アミロイドーシスの複雑な症例に対応できる専門医療スタッフとともに包括的なインフラを備えているため、2023年の市場を独占しました。

治療法別では、関連疾患、特にALアミロイドーシスの管理における有効性が確立されていることから、2023年には化学療法分野が市場の主要シェアを占めました。さらに、併用療法の進歩が化学療法の需要を押し上げました。

ALアミロイドーシスに罹患した患者に対する造血幹細胞移植の認知度が高まっていることから、移植分野は予測期間中に堅調なペースで成長すると予測されています。

世界市場では、高齢化人口の増加と疾患に対する認識の高まりにより、北米が2023年に最大の収益シェアを占めました。

アジア太平洋地域の市場は、慢性疾患の増加とヘルスケア支出の増加により、予測期間中に大きなCAGRを記録すると予測されます。

世界の主な市場企業としては、 Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.などが挙げられます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のアミロイドーシス治療市場の洞察

  • 市場スナップショット
  • アミロイドーシス治療市場力学
    • 促進要因と機会
      • 診断技術の進歩が市場規模を押し上げている
      • 世界中で臨床試験が増加しており、アミロイドーシス治療市場が成長しています。
    • 抑制要因と課題
      • 治療費の高騰により市場の成長が阻害されると予想されます。
  • PESTEL分析
  • アミロイドーシス治療市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のアミロイドーシス治療市場：治療別

  • 主な調査結果
  • イントロダクション
  • 化学療法
  • 免疫抑制薬
  • 移植
  • 支持療法
  • 手術
  • その他

第6章 世界のアミロイドーシス治療市場：エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院・クリニック
  • 外来手術センター
  • 在宅ケア設定
  • その他

第7章 世界のアミロイドーシス治療市場：地域別

  • 主な調査結果
  • イントロダクション
    • アミロイドーシス治療市場評価：地域、2019-2032年
  • 北米
    • 北米：治療、2019-2032年
    • 北米：エンドユーザー別、2019年～2032年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療別、2019-2032年
    • 欧州：エンドユーザー別、2019年～2032年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療、2019年～2032年
    • アジア太平洋地域：エンドユーザー別、2019年～2032年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療、2019年～2032年
    • 中東・アフリカ：エンドユーザー別、2019年～2032年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療別、2019-2032年
    • ラテンアメリカ：エンドユーザー別、2019年～2032年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Amgen Inc.
図表

List of Tables:

  • Table 1 Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 2 Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 3 North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 4 North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 5 U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 6 U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 7 Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 8 Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 9 Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 10 Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 11 UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 12 UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 13 France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 14 France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 15 Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 16 Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 17 Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 18 Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 19 Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 20 Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 21 Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 22 Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 23 Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 24 Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 25 Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 26 Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 27 Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 28 Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 29 China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 30 China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 31 India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 32 India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 33 Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 34 Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 35 Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 36 Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 37 Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 38 Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 39 South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 40 South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 41 Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 42 Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 43 Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 44 Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 45 Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 46 Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 47 Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 48 Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 49 UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 50 UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 51 Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 52 Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 53 South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 54 South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 55 Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 56 Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 57 Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 58 Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 59 Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 60 Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 61 Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 62 Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 63 Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 64 Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • Table 65 Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • Table 66 Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • List of Figures:
  • Figure 1. Global Amyloidosis Treatment Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Amyloidosis Treatment Market, by Treatment, 2023 & 2032 (USD billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Amyloidosis Treatment Market, by End-use, 2023 & 2032 (USD billion)
目次
Product Code: PM5132

The global amyloidosis treatment market size is expected to reach USD 9.79 billion by 2032, according to a new study by Polaris Market Research. The report "Amyloidosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery, and Others), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The amyloidosis treatment market is a critical segment of the broader healthcare landscape. It focuses on therapies for a rare but serious group of diseases characterized by the abnormal deposition of amyloid proteins in various tissues and organs. Amyloidosis is categorized into several types, including AL (light chain), AA (secondary), hereditary forms, and wild-type ATTR (transthyretin amyloidosis). The complexity of these conditions necessitates a diverse array of treatment options, which has led to significant advancements in the market.

The amyloidosis treatment market has evolved continuously over the decades, driven by a deeper understanding of the disease mechanisms and improved diagnostic techniques. Historically, there were limited treatment options for amyloidosis, often resulting in poor patient outcomes. However, the recent introduction of novel therapies such as daratumumab and tafamidis has transformed the management of this condition.

The global amyloidosis treatment market is expanding due to several factors such as rising awareness, ongoing research and development, and a rising aging population. Moreover, advancements in diagnostic technologies, including imaging and biomarker identification, are facilitating earlier diagnosis, which is crucial for the effective treatment of amyloidosis.

Amyloidosis Treatment Market Report Highlights

Based on end use, the home care settings segment in the amyloidosis treatment market is expected to experience substantial growth during the forecast period due to the rising preference for patient-centered care.

The hospitals & clinics segment dominated the market in 2023 due to their comprehensive infrastructure along with specialized medical staff equipped to handle complex cases of amyloidosis.

By treatment, the chemotherapy segment accounted for a major share of the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Moreover, advancements in combination therapies propelled the demand for chemotherapy.

The transplantation segment is projected to grow at a robust pace during the forecast period owing to the rising recognition of hematopoietic stem cell transplantation for patients affected by AL amyloidosis.

In the global market, North America accounted for the largest revenue share in 2023 due to the rising aging population and increased awareness of the disease.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing prevalence of chronic diseases coupled with growing healthcare expenditure.

A few global key market players are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.

Polaris Market Research has segmented the amyloidosis treatment market report based on treatment, end user, and region:

By Treatment Outlook (Revenue, USD Billion, 2024-2032)

  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others

By End User Outlook (Revenue, USD Billion, 2024-2032)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

By Regional Outlook (Revenue, USD Billion, 2024-2032)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Amyloidosis Treatment Market Insights

  • 4.1. Amyloidosis Treatment Market - Market Snapshot
  • 4.2. Amyloidosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Advancements in diagnostic technologies are driving the market size
      • 4.2.1.2. Increasing clinical trials worldwide are driving the amyloidosis treatment market.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The high cost of treatments is expected to impede market growth.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Amyloidosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Amyloidosis Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Amyloidosis Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD billion)
  • 5.4. Immunosuppressive Drugs
    • 5.4.1. Global Amyloidosis Treatment Market, by Immunosuppressive Drugs, by Region, 2019-2032 (USD billion)
  • 5.5. Transplantation
    • 5.5.1. Global Amyloidosis Treatment Market, by Transplantation, by Region, 2019-2032 (USD billion)
  • 5.6. Supportive Care
    • 5.6.1. Global Amyloidosis Treatment Market, by Supportive Care, by Region, 2019-2032 (USD billion)
  • 5.7. Surgery
    • 5.7.1. Global Amyloidosis Treatment Market, by Surgery, by Region, 2019-2032 (USD billion)
  • 5.8. Others
    • 5.8.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

6. Global Amyloidosis Treatment Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 6.3. Hospitals & Clinics
    • 6.3.1. Global Amyloidosis Treatment Market, by Hospitals & Clinics, by Region, 2019-2032 (USD billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Amyloidosis Treatment Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD billion)
  • 6.5. Home Care Settings
    • 6.5.1. Global Amyloidosis Treatment Market, by Home Care Settings, by Region, 2019-2032 (USD billion)
  • 6.6. Others
    • 6.6.1. Global Amyloidosis Treatment Market, by Others, by Region, 2019-2032 (USD billion)

7. Global Amyloidosis Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Amyloidosis Treatment Market Assessment, By Geography, 2019-2032 (USD billion)
  • 7.3. Amyloidosis Treatment Market - North America
    • 7.3.1. North America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.3.2. North America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.3. Amyloidosis Treatment Market - U.S.
      • 7.3.3.1. U.S.: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.3.2. U.S.: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.3.4. Amyloidosis Treatment Market - Canada
      • 7.3.4.1. Canada: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.3.4.2. Canada: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.4. Amyloidosis Treatment Market - Europe
    • 7.4.1. Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.4.2. Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.3. Amyloidosis Treatment Market - UK
      • 7.4.3.1. UK: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.3.2. UK: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.4. Amyloidosis Treatment Market - France
      • 7.4.4.1. France: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.4.2. France: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.5. Amyloidosis Treatment Market - Germany
      • 7.4.5.1. Germany: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.5.2. Germany: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.6. Amyloidosis Treatment Market - Italy
      • 7.4.6.1. Italy: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.6.2. Italy: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.7. Amyloidosis Treatment Market - Spain
      • 7.4.7.1. Spain: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.7.2. Spain: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.8. Amyloidosis Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.8.2. Netherlands: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.9. Amyloidosis Treatment Market - Russia
      • 7.4.9.1. Russia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.9.2. Russia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.4.10. Amyloidosis Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.4.10.2. Rest of Europe: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.5. Amyloidosis Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.5.2. Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.3. Amyloidosis Treatment Market - China
      • 7.5.3.1. China: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.3.2. China: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.4. Amyloidosis Treatment Market - India
      • 7.5.4.1. India: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.4.2. India: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.5. Amyloidosis Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.5.2. Malaysia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.6. Amyloidosis Treatment Market - Japan
      • 7.5.6.1. Japan: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.6.2. Japan: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.7. Amyloidosis Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.7.2. Indonesia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.8. Amyloidosis Treatment Market - South Korea
      • 7.5.8.1. South Korea: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.8.2. South Korea: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.9. Amyloidosis Treatment Market - Australia
      • 7.5.9.1. Australia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.9.2. Australia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.5.10. Amyloidosis Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.5.10.2. Rest of Asia Pacific: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.6. Amyloidosis Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.6.2. Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.3. Amyloidosis Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.3.2. Saudi Arabia: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.4. Amyloidosis Treatment Market - UAE
      • 7.6.4.1. UAE: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.4.2. UAE: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.5. Amyloidosis Treatment Market - Israel
      • 7.6.5.1. Israel: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.5.2. Israel: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.6. Amyloidosis Treatment Market - South Africa
      • 7.6.6.1. South Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.6.2. South Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.6.7. Amyloidosis Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.6.7.2. Rest of Middle East & Africa: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
  • 7.7. Amyloidosis Treatment Market - Latin America
    • 7.7.1. Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
    • 7.7.2. Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.3. Amyloidosis Treatment Market - Mexico
      • 7.7.3.1. Mexico: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.3.2. Mexico: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.4. Amyloidosis Treatment Market - Brazil
      • 7.7.4.1. Brazil: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.4.2. Brazil: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.5. Amyloidosis Treatment Market - Argentina
      • 7.7.5.1. Argentina: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.5.2. Argentina: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)
    • 7.7.6. Amyloidosis Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Amyloidosis Treatment Market, by Treatment, 2019-2032 (USD billion)
      • 7.7.6.2. Rest of Latin America: Amyloidosis Treatment Market, by End-use, 2019-2032 (USD billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Johnson & Johnson Services, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. GSK plc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Takeda Pharmaceutical Company Limited
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Alnylam Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sanofi
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Merck KGaA
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. F. Hoffmann-La Roche Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Ionis Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Bristol-Myers Squibb Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Amgen Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development